A second phase I trial to investigate the safety, tolerability and efficacy of MK-8719
Latest Information Update: 25 Apr 2016
Price :
$35 *
At a glance
- Drugs MK 8719 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- 25 Apr 2016 New trial record